Grace Therapeutics, Inc. filings document material events, operating updates and governance matters for a late-stage biopharma company advancing GTx-104. Form 8-K disclosures cover quarterly results, corporate presentations, the GTx-104 New Drug Application, the FDA Complete Response Letter, and the chemistry, manufacturing and controls and non-clinical subjects cited in that regulatory correspondence.
The filing record also includes disclosures on patent protection for “Nimodipine Parenteral Administration,” exercises and expirations of common warrants issued in private placements, exhibit-based press releases, and amendments to executive letter agreements and compensation arrangements.
Grace Therapeutics, Inc. (GRCE) reported that Opaleye Management Inc., identified as a 10% owner, reported two purchases by Opaleye, L.P.: 21,390 shares at a weighted average of $1.9258 per share on October 22, 2026, and 66,411 shares at a weighted average of $1.7679 per share on October 26, 2026. The weighted averages reflect multiple transactions within respective ranges of $1.91–$1.93 and $1.705–$1.79. No Rule 10b5-1 plan is reported. Opaleye Management disclaims beneficial ownership except to the extent of its pecuniary interest.
Grace Therapeutics, Inc. had a reported purchase of 4,256 common shares by Opaleye, L.P. on October 19, 2026, at $1.88 per share. Opaleye Management Inc., a 10 percent owner, reported the transaction as investment manager of the Fund; the position held directly by Opaleye, L.P. after the purchase was 2,948,610 shares. Opaleye Management may be deemed to beneficially own the Fund's shares, but disclaims beneficial ownership except to the extent of its pecuniary interest. No Rule 10b5-1 plan is reported.
Opaleye Management Inc., a 10% owner, reported three purchases of Grace Therapeutics, Inc. (GRCE) common stock held directly by Opaleye, L.P., the fund it manages. Opaleye, L.P. bought 11,233 shares on October 14, 2026, at a weighted-average price of $1.9349 per share; 23,485 shares on October 15 at $1.9453; and 36,347 shares on October 16 at $1.8917. The reported prices are weighted averages across multiple transactions.
Grace Therapeutics, Inc. (GRCE) reported that Opaleye, L.P. purchased 7,215 shares on October 12, 2026, at $2.0200 per share; 5,340 shares on October 9 at a weighted average price of $2.0446 per share; and 2,077 shares on October 8 at $2.0175 per share. Opaleye Management Inc., a ten percent owner, reported the transactions. The shares are owned directly by Opaleye, L.P., and no Rule 10b5-1 plan is reported.
Opaleye Management, Inc., a ten percent owner of Grace Therapeutics, Inc. (GRCE) and investment manager of Opaleye, L.P., reported three purchases by the fund, which directly owns the shares, totaling 60,490 common shares. Opaleye, L.P. purchased 38,796 shares on October 1, 2026, at a weighted-average price of $2.0353 per share, with transaction prices ranging from $2.00 to $2.04; 20,000 shares on October 2, 2026, at a weighted-average price of $2.0684 per share, with transaction prices ranging from $2.03 to $2.07; and 1,694 shares on October 5, 2026, at $2.0600 per share. No Rule 10b5-1 plan is reported. Opaleye Management may be deemed to beneficially own the fund's shares but disclaims beneficial ownership except to the extent of its pecuniary interest.
Grace Therapeutics, Inc. (GRCE) reports that Opaleye, L.P. purchased 7,849 common shares on September 29, 2026, at $2.09 per share. The Fund’s reported position after the purchase was 2,798,167 shares. Opaleye Management Inc., identified as a 10% owner and the Fund’s investment manager, may be deemed to beneficially own the Fund’s shares but disclaims beneficial ownership except to the extent of its pecuniary interest. No Rule 10b5-1 plan is reported.
Grace Therapeutics, Inc. (GRCE) shares were purchased by Opaleye, L.P. in two reported transactions: 9,771 shares on September 21, 2026, and 5,318 shares on September 23, 2026, each at $2.10 per share. No Rule 10b5-1 plan is reported.
The amendment corrects the amount of securities beneficially owned after the transactions. The shares are owned directly by Opaleye, L.P.; Opaleye Management, Inc., its investment manager, may be deemed to beneficially own them and disclaims beneficial ownership except to the extent of its pecuniary interest.
Grace Therapeutics, Inc. (GRCE) reported that Opaleye, L.P. purchased 9,771 shares of common stock on September 21, 2026, and 5,318 shares on September 23, 2026, at $2.10 per share in each transaction. Opaleye Management, Inc., a ten percent owner and the Fund’s investment manager, may be deemed to beneficially own the Fund’s shares but disclaimed beneficial ownership except to the extent of its pecuniary interest therein.
Grace Therapeutics, Inc. (GRCE) director Edward Neugeboren received a grant of stock options for 12,200 shares of common stock on September 17, 2026. The options have an exercise price of $2.13 per share and expire on September 16, 2036. Half of the award vests immediately, with the remaining half vesting in substantially equal monthly installments over 12 months, subject to continuous service. No Rule 10b5-1 trading plan is reported for this grant.
Grace Therapeutics, Inc. (GRCE) reported that director Brian A. Davis received a grant of stock options covering 12,200 shares of Common Stock on September 17, 2026. The options have an exercise price of $2.13 per share and expire on September 16, 2036.
According to the vesting terms, 50% of the option vests on the grant date and the remaining 50% vests in substantially equal monthly installments over 12 months, subject to his continuous service. After this grant, he holds 12,200 options directly. No Rule 10b5-1 trading plan is reported.